Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Stonerock

Vascular Surgery Florence, SC Medical Doctor

NPI 1205860210 CMS profile 236502

805 Pamplico Hwy, Ste B-300, Florence, SC 29505

Open in the dashboard

General payments

$5,483

112 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Stonerock of Florence, SC is reported in the CMS Open Payments database as having received $5,483 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,475 26
2024 General $860 11
2023 General $605 8
2022 General $1,058 20
2021 General $189 7
2020 General $543 18
2019 General $753 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Stonerock
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Charles Stonerock were reported at $1,475. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Charles Stonerock Vascular Surgery median Middle half National median
2019 $753 $796 $226–$2,363 $163
2020 $543 $348 $118–$1,110 $114
2021 $189 $471 $158–$1,421 $132
2022 $1,058 $725 $222–$2,183 $149
2023 $605 $836 $257–$2,440 $160
2024 $860 $909 $252–$2,619 $164
2025 $1,475 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,254 40 payments
  2. Stryker Corporation $673 11 payments
  3. Cook Medical LLC $473 7 payments
  4. Boston Scientific Corporation $388 10 payments
  5. Inari Medical, Inc. $312 4 payments
  6. Cardiovascular Systems Inc. $236 11 payments
  7. Penumbra, Inc. $230 5 payments
  8. Shockwave Medical, Inc $190 6 payments
  9. Medtronic Vascular, Inc. $147 5 payments
  10. Cardinal Health 200, LLC $120 1 payment
  11. Other $462 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,468 111 payments
  2. Travel and Lodging $15 1 payment
Products named General payments · program years 2019–2025
  1. EXCLUDER Conformable AAA Endoprosthesis with Active Control $741 10 payments
  2. GORE VIABAHN VBX Balloon Expandable Endo $647 4 payments
  3. Zilver PTX $453 6 payments
  4. FLOWTRIEVER $416 6 payments
  5. CT THROMBECTOMY SYSTEM KIT $330 5 payments
  6. FLOWTRIEVER CATHETER, S $330 5 payments
  7. VIABAHN VBX Balloon Expandable Endoprosthesis $309 3 payments
  8. Peripheral Orbital Atherectomy System $204 9 payments
  9. Endurant $147 5 payments
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $142 4 payments
  11. Other $2,249 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

317

Median for General Surgery: 59

Drug cost

$3,066

Median for General Surgery: $393

Branded share of claims

38.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 137 $2,166
Clopidogrel Clopidogrel Bisulfate Brand 104 $518
Atorvastatin Calcium Generic 28 $197
Gabapentin Generic 12 $102
Oxycodone Hcl Generic 17 $46
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 19 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$177,603

Medicare's payments for the services billed

Medicare patients

1,195

Average age 74

Services billed

2,318

604 women, 591 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 49%
Ischemic heart disease 47%
Chronic kidney disease 39%
Heart failure 36%
COPD 32%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record